Incremental benefits of novel pharmaceuticals in the United Kingdom 77 4♣ 23. Darrow JJ, Avorn J, Kesselheim AS. FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA. 2020;323(2):164. 24. Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology. JAMA Intern Med. 2015;175(8):1389. 25. Gharzai LA, Jiang R, Wallington D, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate metaanalysis. Lancet Oncol. 2021;22(3):402-410. 26. Cherla A, Naci H, Kesselheim AS, Gyawali B, Mossialos E. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. JAMA Intern Med. 2021;181(4):490. 27. van Harten WH, Wind A, de Paoli P, Saghatchian M, Oberst S. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 2016;17(1):18-20. 28. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors Influencing the Decline in Stroke Mortality. Stroke. 2014;45(1):315-353. 29. Ford ES, Capewell S. Proportion of the Decline in Cardiovascular Mortality Disease due to Prevention Versus Treatment: Public Health Versus Clinical Care. Annu Rev Public Health. 2011;32(1):5-22. 30. Cucchi DGJ, Polak TB, Ossenkoppele GJ, et al. Two decades of targeted therapies in acute myeloid leukemia. Leukemia. 2021;35(3):651-660. 31. Duetz C, Cucchi DGJ, Polak TB, et al. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. Br J Haematol. Published online October 10, 2021. 32. Cucchi DG, Polak TB, Ossenkoppele GJ, Rowe JM, Estey EH. The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III. Blood. Published online January 12, 2022. 33. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-1222. 34. Dooper M. Advies uitbrengen over subgroepen: NVMO-leden steunen aanpassing van werkwijze commissie BOM. Med Oncol. 2017;20(4):38-39. 35. Liu R, Staller K. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives. Drug Des Devel Ther. 2020;Volume 14:13911400.
RkJQdWJsaXNoZXIy MTk4NDMw